ASK REDCHAT ANYTHING ABOUT PRELUDE THERAPEUTICS INCORPORATED
Prelude Therapeutics Incorporated (NASDAQ: PRLD)
Listen to this Section
$3.98
+0.3200
(
+8.74% )
246.5K
Sign up for The Small Stocks Big Money Newsletter and receive free small-cap news and insights.
Clinical Trial Pipeline Stages
| Drug Name |
Stage |
| PRT3645 (CDK4/6 inhibitor) + KEYTRUDA®DetailsCancer |
Phase 2 |
| PRT543 (PRMT5 inhibitor)DetailsMyelofibrosis, Solid tumor/s, Myelodysplastic syndrome, Cancer |
Phase 1 |
| PRT3645 (CDK4/6 inhibitor)DetailsHead and neck cancer, Glioblastoma, Non-small cell lung carcinoma, Breast cancer |
Phase 1 |
| PRT2527 (CDK9 inhibitor)DetailsAcute myeloid leukemia, Hematologic malignancies, Solid tumor/s |
Phase 1 |
| PRT3789 [SMARCA2 degrader]DetailsNon-small cell lung carcinoma, Cancer |
Phase 1 |
| PRT7732 [SMARCA2 degrader]DetailsCancer, Non-small cell lung carcinoma |
Phase 1 |
| PRT1419 (MCL1 inhibitor)DetailsHematologic malignancies, B-cell malignancies, Relapsed/refractory acute myeloid leukemia, Solid tumor/s |
Failed |
| PRT811 (PRMT5 inhibitor)Detailsprimary central nervous system lymphomas, Cancer, Glioblastoma |
Failed |
Market Data
| Open |
$3.98 |
| Previous Close |
$3.66 |
| Volume |
246.5K |
| Market Cap |
$291.50M |
| Day Range |
$3.62 - $4.33 |
| 52 Week Range |
$0.75 - $5.54 |
| Shares Outstanding |
79.65M |
| Change % |
+8.74% |
| Net Change |
▲ 0.3200 |
| Insider Ownership |
0.01% |
| Exchange |
NASDAQ |
| Sector | Healthcare |
| Industry | Medicinal Chemicals and Botanical Products |
| IPO Year | 2020 |
| Country | United States |
| Underwriter | IPO Intelligence Only |
Insider Ownership Transactions
Total Amount Purchased:
-1,863,877.00
| Date |
Type |
Amount Purchased |
Purchaser |
| 2023-12-13 |
Sale |
-593452.00 |
BAKER BROS. ADVISORS LP |
| 2023-10-06 |
Sale |
-9375.00 |
Huang Jane |
SEC Filings
| Form Type |
Description |
Pages |
Date |
| 10-q |
Quarterly Reports |
67 |
Nov 12, 2025 |
| 8-k |
8K-related |
38 |
Nov 12, 2025 |
| 4 |
Insider transactions |
1 |
Nov 07, 2025 |
| 8-k |
8K-related |
40 |
Nov 04, 2025 |
| 3 |
Insider transactions |
2 |
Oct 20, 2025 |
| 4 |
Insider transactions |
2 |
Oct 20, 2025 |
| 8-k |
8K-related |
12 |
Oct 17, 2025 |
| 4 |
Insider transactions |
1 |
Oct 07, 2025 |
| 8-k |
8K-related |
10 |
Sep 19, 2025 |
| 10-q |
Quarterly Reports |
66 |
Aug 14, 2025 |